Pub. Date : 2013 Dec 1
PMID : 24062397
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Recent data have suggested that the benefit of aspirin after CRC diagnosis is limited to patients with PIK3CA-mutant cancers. | Aspirin | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Homo sapiens |
| 2 | We sought to determine the predictive utility of PIK3CA mutation for benefit from both cyclooxygenase-2 inhibition and aspirin. | Aspirin | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Homo sapiens |
| 3 | In contrast, regular aspirin use after CRC diagnosis was associated with a reduced rate of CRC recurrence in patients with PIK3CA-mutant cancers (HR, 0.11; 95% CI, 0.001 to 0.832; P = .027; (P)INTERACTION = .024) but not in patients lacking tumor PIK3CA mutation (HR, 0.92; 95% CI, 0.60 to 1.42; P = .71). | Aspirin | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Homo sapiens |
| 4 | In contrast, regular aspirin use after CRC diagnosis was associated with a reduced rate of CRC recurrence in patients with PIK3CA-mutant cancers (HR, 0.11; 95% CI, 0.001 to 0.832; P = .027; (P)INTERACTION = .024) but not in patients lacking tumor PIK3CA mutation (HR, 0.92; 95% CI, 0.60 to 1.42; P = .71). | Aspirin | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Homo sapiens |
| 5 | Our findings are concordant with recent data and support the prospective investigation of adjuvant aspirin in PIK3CA-mutant CRC. | Aspirin | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Homo sapiens |